Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer.

Key facts

Study ID

NCT01429064

Run by

Orion Corporation, Orion Pharma

People needed

76

Starts

2011-06-01

Expected to finish

2015-11-01

Last updated by the study team

2017-02-20

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent
• Successful completion of study protocol 3104001
• Response or stable disease in study 3104001 at week 12

You may not qualify if…

• New serious concurrent medical condition
• Not able to swallow the study drug

Where it is running

• The Urology Center of Colorado — Wheat Ridge, Colorado, United States
• Eastern CT Hematology and Oncology Associates — Norwich, Connecticut, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Carolina Urologic Research Center — Myrtle Beach, South Carolina, United States
• Klinika onkologie a radioterapie LFUK a FN — Hradec Králové, Czechia
• East-Tallinn Central Hospital — Tallinn, Estonia
• Helsinki University Central Hospital — Helsinki, Finland
• Kuopio University Hospital — Kuopio, Finland
• Oulu University Hospital — Oulu, Finland
• Tampere University Hospital — Tampere, Finland
• Turku University Hospital — Turku, Finland
• Saint Louis Hospital — Paris, France
• Institut Gustave Roussy — Villejuif, France
• Queen Elizabeth Hospital — Birmingham, United Kingdom
• Velindre Cancer Centre — Cardiff, United Kingdom
• Christie Hospital — Manchester, United Kingdom
• Churchill Hospital — Oxford, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.